Expectations Influence Effectiveness of Migraine Medication


Patients’ expectations influenced the effects of both medications and placebos in a recent study and highlighted the importance of the power of suggestion in the field of medicine.

Researchers studied 66 migraineurs over the course of more than 450 migraine attacks and found that when they provided positive information about a placebo and the common migraine medication Maxalt (rizatriptan), the effectiveness of both increased. This observation suggested that a positive message and a powerful medication are important in improved quality clinical care. Continue Reading

Adolescents With Migraine Benefit from Combination Medication

Adolescents who suffer from migraine may find relief with a combination of sumatriptan and naproxen sodium (suma/nap), according to a study published online last month in Pediatrics.

Researchers studied 600 teens, ages 12 to 17, who experienced two to eight migraine attacks per month for at least six months. The first migraine during the study period was treated with a placebo. If the pain persisted two hours later, the teens were assigned to a placebo group or to a group receiving different doses of suma/nap: 10/60 mg, 30/180 mg or 85/500 mg. Researchers then evaluated who was pain-free two hours later. Continue Reading

SUMAVEL DosePro® Available this Month for Migraine and Cluster Headache

Approved by the FDA in July, SUMAVEL DosePro is being launched this month by Zogenix in partnership with Astellas. The first-of-its-kind needle-free injection system delivers a liquid form of sumatriptan (Imitrex®) directly through the skin (subcutaneously). It is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes in adults. Continue Reading